Forest Laboratories and Almirall announced that the FDA has approved Tudorza Pressair (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
SIGN IN WITH ONE OF YOUR SOCIAL ACCOUNTS
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH ONE OF YOUR SOCIAL ACCOUNTS
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a password reset link.
ENTER NEW PASSWORD